A Study of LP-168 in Healthy Volunteers

NCT05432713 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis
NMO Spectrum Disorder

Interventions

DRUG: LP-168 tablet
DRUG: LP-168 Placebo tablet

Sponsor

Guangzhou Lupeng Pharmaceutical Company LTD.